China’s Adagene Gears Up for IPO, Seeking 125 Million for Cancer Therapy Development
Targeting up to 125 million, China’s cancer immunotherapy developer Adagene filed for IPO on January 19th and will later list on the Nasdaq. Based in Suzhou, China, Adagene is leveraging …
Read More